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SUMMARY 
 
Acetylation is a posttranslational 
modification that alters the biological 
activities of proteins by affecting their 
association with other proteins or DNA, their 
catalytic activities, or their subcellular 
distribution. The acetyltransferase P/CAF is 
autoacetylated and acetylated by p300 in vivo. 
P/CAF autoacetylation is an intramolecular or 
intermolecular event. Intramolecular 
acetylation targets five lysines within the 
nuclear localization signal at the P/CAF C 
terminus. We analyzed how the subcellular 
distribution of P/CAF is regulated by 
intramolecular autoacetylation, and found 
that a P/CAF mutant lacking histone 
acetyltransferase activity accumulated 
primarily in the cytoplasm. This cytoplasmic 
fraction of P/CAF is enriched for 
nonautoacetylated P/CAF. In addition, P/CAF 
deacetylation by HDAC3 and in minor degree 
by HDAC1, HDAC2 or HDAC4, leads to 
cytoplasmic accumulation of P/CAF. 
Importantly, our data show that P/CAF 
accumulates in the cytoplasm during 
apoptosis. These results reveal the molecular 
mechanism of autoacetylation control of 
P/CAF nuclear translocation, and suggest a 
novel pathway by which P/CAF activity is 
controlled in vivo. 
 
INTRODUCTION 
  
p300/CBP-associated factor (P/CAF, 
also known as PCAF) was initially identified as a 
CBP/p300 binding protein, due to its sequence 
similarity to the yeast histone acetyltransferase 
(HAT) GCN5 (yGCN5) (1). Both P/CAF and 
GCN5 belong to the GCN5 family of HATs, and 
show sequence conservation in the regions 
responsible for HAT activity, the bromodomain 
and the ADA2 region (responsible for binding 
the yADA2 cofactor) (2,3). In addition, P/CAF 
activates transcription; to do that it requires its 
intrinsic HAT activity (4,5).  
P/CAF is found in a complex comprising 
more than 20 polypeptides. Some of these 
polypeptides are similar to TATA box binding 
protein (TBP)-associated factors (TAFS), while 
others contain a histone fold domain (6). P/CAF 
has an intrinsic ability to acetylate nucleosomal 
histones in vitro and in vivo, and also acetylates 
nonhistone proteins such as p53 (7), E2F (8,9), 
YY1 (10), NFkB (11), SREBP (12), Ku70 (13), 
and Smad7, 2 and 3 (14,15). Acetylation affects 
the in vivo functions of these proteins. Moreover, 
P/CAF exists as an acetylated protein in vivo. 
P/CAF is autoacetylated and acetylated by p300, 
but not by CBP. P/CAF autoacetylation takes 
place via intramolecular and intermolecular 
mechanisms (16). Intramolecular acetylation 
targets five lysines in the nuclear localization 
signal (NLS) at amino acids 416–442 of the C 
terminus. Autoacetylation leads to an increase in 
P/CAF HAT activity in vitro (16). Furthermore, 
P/CAF physically associates with HDAC1, 
SIRT1, and HDAC3 histone deacetylases 
(HDACs) (17-19). HDAC3 deacetylates P/CAF 
(17). This suggests that multiple HDACs target 
P/CAF and other factors that are not histones 
(17,19-22). In addition to its acetyltransferase 
activity, P/CAF has intrinsic ubiquitination 
activity, which is important in controlling Hdm2 
protein levels (23). 
P/CAF may have a role in DNA damage 
response and apoptosis due to its ability to 
acetylate p53, E2F1, and Ku70 (8,9,13,24-27). 
Moreover, specific modifications of chromatin 
are likely to play an essential role in apoptosis 
induction. In support of this role, treatment with 
HDAC inhibitors induces apoptosis (28). Recent 
data have shown that during apoptosis, global 
changes in histone modifications occur (29-34), 
including histone acetylation (34,35). At the 
same time, the activity of many HAT and HDAC 
enzymes is affected during apoptosis. For 
example, HAT CBP/p300 is cleaved during 
apoptosis in the central nervous system (36). 
More recently, it was shown that HDAC-4 and 
HDAC-3 nuclear–cytoplasmic shuttling 
promotes apoptosis (35,37) 
Although P/CAF is a nuclear protein, its 
nuclear localization was reported to change in 
response to cellular or extracellular signals  
(17,38). However, the molecular mechanisms 
governing this transition were not known. Here, 
we report that P/CAF localization is regulated by 
intramolecular autoacetylation.  
 
EXPERIMENTAL PROCEDURES 
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Cell culture and transfections 
NIH3T3 fibroblasts were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM; 
Invitrogen), supplemented with 10% calf serum 
(CS, Invitrogen). HeLa, CV1COS, HTC119, and 
293T cells were grown in DMEM supplemented 
with 10% fetal calf serum (FCS, Invitrogen). 
Transient transfections were performed either by 
standard calcium phosphate coprecipitation with 
3 µg of each expression vector, or with 
lipofectamine reagent (Invitrogen). Transfected 
cells were washed after 14 h and harvested 24 h 
after transfection. Cells were then treated with 
either  a HDAC inhibitor, trichostatin A (TSA) 
(0, 100, or 150 mM for 12 h), an inhibitor of 
nuclear export, leptomycin B (LMB) (20 nM 
added to the culture medium for 2–8 h), a 
proteasome inhibitor, MG132 (10 µM for 12 h), 
or dexamethasome 2 muM, followed by 
collection and analysis. 
Plasmids and recombinant proteins  
P/CAF(352-832) and P/CAF(352-832)ΔHAT 
were cloned from PCX-GFP-P/CAF(FL)-Flag 
and PCX-GFP-P/CAFΔHAT -Flag (16) by PCR 
into the pcDNA3 vector (Invitrogen). A mutation 
was introduced at leucine 606 in P/CAF cDNA 
using the QuikChange mutagenesis kit 
(Stratagene) and following the manufacturer’s 
instructions. The mutation was verified by DNA 
sequencing. pcDNA3-HDAC1-Flag, pcDNA3-
HDAC4 and pcDNA3-HDAC2 were previously 
described (39). pcDNA3-Flag-HDAC3 and 
pSuper-shRNAHDAC3 were a gift from Dr. X.-
J. Yang, and pcDNA3-Sirt1 and pcDNA3-GFP-
Sirt2 were gifts from Dr. A. Vaquero. pGEX-
P/CAF(352-832) and pGEX-P/CAF(352-
832)ΔHAT   were previously described (16). 
pGEX-Importin α1 and Importin β were gifts 
from Dr. M. Gorospe and Drs. Y. Yoneda and T. 
Sekimoto, respectively.  
Indirect immunofluorescence 
Cells on coverslips were fixed in 4% 
paraformaldehyde in PBS for 30 min at room 
temperature and permeabilized with methanol for 
10 min. After blocking with 3% BSA in PBS and 
0.1% Tween 20 for 1 h at room temperature, 
coverslips were incubated with a 1:200-500 anti-
P/CAF (Upstate Biotechnology), 1:500 anti-
acetylated histone H3 (Upstate Biotechnology), 
and/or 1:100 anti-Flag (Upstate Biotechnology) 
antibodies in PBS and 3% BSA for 2 h. This was 
followed by incubation for 1 hr with goat anti-
rabbit IgG, used at a 1:250 dilution in PBS and 
3% BSA. After each antibody incubation, the 
coverslips were washed four times for 10 min 
each time with PBS and 0.05% Tween 20 at 
room temperature. Cells fixed in 4% 
paraformaldehyde in PBS for 30 min at room 
temperature were incubated with fluorescent 
Annexin V (Roche) for 2 h. The nuclei were 
stained with DAPI. To distinguish endogenous 
and ectopic, transfected P/CAF 
immunofluorescence signals different laser 
intensities were used at the confocal microscope. 
In addition, transfected cells were followed by 
GFP coexpression (see Supplementary Figure 1).  
Cell extract preparation and immunoblotting 
and immunoprecipitation assays 
Total cell extracts were prepared in IPH buffer 
(40) by keeping the cells on ice for 20 min or for 
the indicated time, followed by centrifugation at 
12 000xg for 10 min at 4 °C. All buffers 
contained protease inhibitors (Boehringer). 
Immunoblotting was performed using standard 
procedures and visualized using an ECL kit 
(Amersham). The antibodies were acetyl-lys 
antibody (Chemicon) used at a 1:1,000 dilution, 
anti-P/CAF antibody (Santa Cruz Biotechnology) 
used at a 1:1,000 dilution, and anti-Flag M2 
antibody (Upstate Biotechnology) used at a 
1:100. Immunoprecipitation analyses were 
performed as described elsewhere (41), except 
for the in vivo acetylation detection and IP-HAT 
assays, in which the IPH buffer was changed for 
RIPA buffer. 
HAT and AT assays 
In vitro HAT and AT assays were performed as 
described elsewhere (4,8). P/CAF 
autoacetylation was performed under the same 
conditions than HAT assays, but in the absence 
of histones (16). 
In vitro translation, recombinant proteins, and 
pull-down assay 
In vitro translations and GST pull-downs were 
performed essentially as described previously 
(41). GST and GST fusion proteins were 
expressed in Escherichia coli XA90 using the 
pGEX (Pharmacia) vector system for 4 h at 30 
°C after 0.1mM IPTG was added. Purification 
from crude bacterial lysates was performed as in 
(41). The buffer used for the pull-downs was a 
variation of Z´ (25 mM HEPES pH 7.5, 12.5 mM 
MgCl2, 20% glycerol, 0.1% NP40, and 250 mM 
KCl). 
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RESULTS 
 
P/CAF lacking HAT activity localizes to the 
cytoplasm 
Previous work has shown that amino 
acids 428–442 of P/CAF contain the NLS. 
Mutations of lysines 428, 430, 441, and 442 to 
arginines leads to P/CAF cytoplasmic 
accumulation (16). These lysines are the targets 
of intramolecular autoacetylation (16). However, 
mutations of the NLS lysines are not direct proof 
of the autoacetylation requirement, as the lysines 
themselves are essential for NLS function. Here, 
we investigated the role of P/CAF intramolecular 
autoacetylation on P/CAF subcellular 
distribution using a HAT-domain mutant. P/CAF 
(352-832)ΔHAT cannot be autoacetylated 
(Figure 1A and 1C), because it lacks the N-
terminal part of the protein, the region required 
for intermolecular acetylation (16) and HAT 
catalytic activity (Figure 1B). HAT catalytic 
activity is required for intramolecular 
autoacetylation (Figure 1C). However, P/CAF 
(352-832)ΔHAT retains the NLS (Figure 1A). 
First, we analyzed the cellular localization of 
P/CAF(352-832) and P/CAF(352-832)ΔHAT. To 
do this, we transfected CV1COS cells with either 
P/CAF(352-832) or P/CAF(352-832)ΔHAT. The 
cellular distribution of P/CAF was analyzed by 
immunostaining using an antibody that 
specifically recognizes P/CAF. P/CAF(352-832) 
signal was found exclusively in the nucleus, 
whereas P/CAF(352-832)ΔHAT was located 
predominantly in the cytoplasm (Figure 1D).  
To confirm these results, we constructed 
a P/CAF HAT mutant (L606A) (Figure 1A) that 
had only a limited ability to acetylate histones 
and it is not able to autoacetylate (Figure 1B and 
1C). We then tested the cellular localization of 
this mutant. CV1COS cells were transfected 
either with P/CAF(352-832) or with P/CAF(352-
832)L606A, and their localizations were revealed 
by immunostaining using an antibody that 
specifically recognizes P/CAF. As expected, 
P/CAF(352-832) was nuclear and P/CAF(352-
832)L606A was distributed in both the nucleus 
and the cytoplasm (Figure 1D). These results 
suggest that P/CAF autoacetylation might be 
involved in its cellular distribution. 
To determine whether this result was 
specific to the CV1COS cell line used in these 
experiments, we examined the subcellular 
localization of P/CAF(352-832) and P/CAF(352-
832)ΔHAT in different cell lines. P/CAF(352-
832) was found mainly in the nuclei in all 
analyzed cell types (Table 1). In contrast, 
varying levels of the P/CAFΔHAT mutant were 
distributed between the nucleus and the 
cytoplasm (Table 1). Taken together, these 
results suggest that P/CAF requires HAT activity 
and the NLS to localize in the nucleus. 
We next tested whether intramolecular 
autoacetylation might regulate the localization of 
full-length P/CAF. To do this, we transfected 
CV1COS cells either with P/CAF full length 
(FL) or with P/CAFΔHAT-FL  and revealed their 
localization by immunostaining using an 
antibody that specifically recognizes P/CAF. As 
expected, P/CAF-FL was mainly nuclear (68% 
of the analyzed cells) and P/CAFΔHAT-FL  
partially cytoplasmic (57% of the analyzed cells 
were cytoplasmic, 28% were distributed between 
nucleus and cytoplasm and 15% were nuclear) 
(Figure 1E). We next examined the subcellular 
localization of P/CAF-FL and P/CAFΔHAT-FL 
in different cell lines (Hela, NIH3T3 and 293T). 
P/CAF-FL was found mainly in the nuclei in all 
analyzed cell types. In contrast P/CAFΔHAT-FL 
was distributed between the nucleus and the 
cytoplasm at similar levels than P/CAF(352-
832)ΔHAT (data not shown). These results 
indicate that P/CAF autoacetylation might be 
involved in its cellular distribution. We 
performed some experiments using P/CAF(352-
832)ΔHAT  or P/CAFΔHAT-FL fused  to GFP 
and Flag epitopes at the N-terminus of the 
protein. Surprisingly, in these cases, P/CAF 
(352-832)ΔHAT  was enriched in the nucleus 
(data not shown), probably due to (i) a 
conformational change in P/CAF protein induced 
by the epitopes or (ii) a change in the 
accessibility of the P/CAF NLS in the fusion 
proteins. 
 
P/CAF nuclear localization correlates with 
autoacetylation 
As HAT activity is required for P/CAF 
nuclear accumulation, we next sought to confirm 
that P/CAF nuclear localization correlates with 
autoacetylation. To that end, we transfected 
P/CAF(352-832), P/CAF(352-832)ΔHAT, and 
P/CAF(352-832)L606A into CV1COS cells. The 
transfected proteins were recovered by 
immunoprecipitation and their acetylation status 
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was analyzed by immunoblot using an antibody 
that specifically recognizes acetylated lysines. 
Only nuclear P/CAF was acetylated in vivo 
(Figure 2A, lane 1). In contrast, cytoplasmic 
P/CAFs lacking HAT activity were not 
acetylated in vivo (Figure 2A, lanes 2 and 3).  
We then treated P/CAF(352-832) and 
P/CAF(352-832)ΔHAT-transfected cells with 
varying amounts of the HDAC inhibitor TSA. 
Subsequently, the P/CAF location was analyzed 
by immunostaining. As expected, TSA did not 
modify the P/CAF cellular distribution (Figure 
2B), probably because cytoplasmic P/CAF(352-
832)ΔHAT is a nonacetylated protein, and 
therefore is not affected by changes in HDAC 
activity. 
 
Proteasome inhibition partially reverses 
P/CAF cytoplasmic accumulation  
Once we had confirmed that P/CAF 
acetylation correlates with localization to the 
nucleus, we sought to understand the molecular 
mechanisms responsible for this cellular 
distribution. 
Autoacetylation could affect the 
localization of P/CAF(352-832) by affecting 
nuclear import or nuclear export. The recognition 
of NLS-containing proteins in the cytoplasm is 
mediated by the heterodimeric importin-α/β 
receptor, in which the importin α subunit is the 
saturable component of the receptor, and the 
importin β targets the NLS-containing protein in 
the nuclear pore complex (42,43). Thus, we 
asked whether P/CAF(352-832) directly bound 
importin α or β, and whether autoacetylation 
affected this interaction in vitro. As shown in 
Figure 3A, GST-P/CAF(352-832) interacted with 
importin-α1 in an in vitro pull down assay. 
Moreover, P/CAF(352-832) bound to GST-
importin-β in vitro (Figure 3B). In addition, 
P/CAF(352-832) autoacetylation decreased these 
interactions (Figure 3A, lanes 3 and 4; Figure 
3B, lane 3). To confirm these results, we 
transfected CV1COS cells with P/CAF or 
P/CAF∆HAT, prepared whole cell extracts from 
the transfected cells, and used them for pull-
down experiments with GST, GST-importin α1, 
and GST-importin β columns. Both P/CAF and 
P/CAF∆HAT interacted efficiently with importin 
α1 and GST-importin β (Figure 3C). These 
results suggest that nuclear import was not the 
cause of the observed P/CAF cellular 
distribution, probably because cytoplasmic 
P/CAF, which recognized the heterodimeric 
importin-α/β receptor, was always 
nonacetylated, as we showed in Figure 2.  
To gain further insight into how P/CAF 
autoacetylation regulates subcellular distribution, 
we analyzed whether nuclear export is affected 
by autoacetylation. To do this, we transfected 
CV1COS cells with P/CAF(352-832), 
P/CAF(352-832)ΔHAT, or GFP-Sirt2 (as a 
control) and treated them with leptomycin B 
(LMB), which impairs CRM1-dependent nuclear 
export. P/CAF localization was determined by 
immunostaining with an antibody that 
specifically recognizes P/CAF. Blocking nuclear 
export did not affect either P/CAF(352-832) 
(nuclear localization) or P/CAF(352-832)ΔHAT 
(cytoplasmic localization), but nuclear export of 
GFP-Sirt2 was affected [as described in (44)] 
(Figure 4A). 
The above results suggest that 
cytoplasmic P/CAF is efficiently imported into 
the nucleus. What happens to nonacetylated 
nuclear P/CAF? The results shown in Figure 4A 
suggest that is not actively exported to the 
cytoplasm. Thus, nuclear nonacetylated protein 
may be degraded by proteolytic processing. We 
therefore tested whether the proteasome inhibitor 
MG132 could reverse the cytoplasmic 
localization of P/CAFΔHAT. To this end, we 
transfected CV1COS cells with P/CAF(352-832) 
or P/CAF(352-832)ΔHAT, and then treated them 
with MG132, which blocks proteasome-mediated 
degradation. The P/CAF localization was 
determined by immunostaining with an antibody 
that specifically recognizes P/CAF. Blocking 
protein degradation induced the accumulation of 
P/CAF in PML bodies (data not shown). 
However, it did not significantly alter the 
nuclear/cytoplasmic distribution of P/CAF 
(Figure 4B). In contrast, MG132 treatment 
allowed a partial accumulation of P/CAF(352-
832)ΔHAT  in the nucleus; the protein was 
distributed between the nucleus and cytoplasm in 
70% of the cells (Figure 4B). Under these 
conditions, nonautoacetylated P/CAF also 
accumulated in the PML and in other cell bodies 
(data not shown).  
 
P/CAF deacetylation by HDAC3 promotes 
P/CAF cytoplasmic accumulation 
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Our results thus far suggested that 
autoacetylation was important in promoting the 
nuclear localization of P/CAF. On the other 
hand, it had previously been shown that some 
HDACs bind P/CAF (17-19), and that HDAC3 
inhibits P/CAF autoacetylation (17). Therefore, 
we tested whether deacetylation of P/CAF by 
HDAC1, HDAC2, HDAC3, HDAC4 or SIRT1 
affected P/CAF nuclear localization. To do this, 
we transfected CV1COS cells with P/CAF(352-
832) in the presence or absence of coexpressed 
Flag-HDAC1, HDAC2, Flag-HDAC3,  HDAC4 
or SIRT1. The cellular localization of P/CAF 
was then analyzed by immunostaining with 
antibodies specific to P/CAF. Although HDACs 
1, 2, and 4 caused P/CAF localization to switch 
from primarily nuclear to both nuclear and 
cytoplasmic, only coexpression of HDAC3 
efficiently promoted the cytoplasmic localization 
of P/CAF (Figure 5A). The specific effect of 
HDAC3 was confirmed by using shRNA which 
partially blocks the expression of HDAC3 
(shRNA HDAC3) (Fig 5B) and control shRNA 
(shRNA C). The results in Fig. 5B show that in 
the presence of low levels of HDAC3, P/CAF 
cytoplasmic accumulation decreases. These 
results  were consistent with our idea that 
intramolecular acetylation is required for P/CAF 
nuclear localization. This transition correlated 
with P/CAF deacetylation (Figure 5C, lane 2). 
To further confirm that the observed effect on 
P/CAF localization was due to deacetylation, we 
added the HDAC inhibitor TSA to the 
transfected cells 10 h before collection. We then 
analyzed the P/CAF localization. HDAC3 in the 
presence of TSA could not promote the P/CAF 
cytoplasmic transition (Figure 5D). This 
correlated with high levels of P/CAF 
autoacetylation in vivo (Figure 5D, lane 5). 
Finally, we sought to establish whether 
cytoplasmic P/CAF was active. To that end, we 
transfected CV1COS cells with P/CAF(352-832) 
in the presence or absence of coexpressed Flag-
HDAC3. Then, we immunoprecipitated P/CAF 
and determined the HAT activity associated with 
the immunopellets in an in vitro HAT assay. The 
results show that both nuclear and cytoplasmic 
P/CAF were capable of acetylating histones, 
although a slight decrease in HAT activity was 
observed in cytoplasmic nonautoacetylated 
P/CAF, (Figure 5E) in agreement with previous 
results (16). We next tested whether HDAC3 
expression might promote cytoplasmic 
accumulation of full-length P/CAF. To do this, 
we transfected CV1COS cells with P/CAF-FL  
and HDAC3 and revealed their localization by 
immunostaining using an antibody that 
specifically recognizes P/CAF and Flag epitope. 
As expected, coexpression of HDAC3 promoted 
the cytoplasmic  or nuclear and cytoplasmic 
localization of P/CAF (64% of the analyzed 
cells) (Figure 5F). On the other hand, HDAC3 in 
the presence of TSA could not induce P/CAF 
cytoplasmic accumulation (Figure 5F). 
Of the assayed HDACs (HDAC1, HDAC2, 
HDAC3, HDAC4 and SIRT1), HDAC3 was the 
enzyme that altered more efficiently P/CAF 
cellular localization (Figure 5A). It had been 
shown previously that HDAC3 binds P/CAF in 
C2C12 cells (17). We sought to establish 
whether the P/CAF–HDAC3 interaction also 
took place under our experimental conditions. 
Thus, we transfected CV1COS cells with 
P/CAF(352-832) and/or Flag-HDAC3 DNA 
plasmids and analyzed the localization of P/CAF 
and HDAC3 by immunostaining with antibodies 
against P/CAF and the Flag epitope. The proteins 
colocalized when they were expressed together 
(Figure 6A). To confirm this result, we 
immunoprecipitated Flag-HDAC3 and analyzed 
for the presence of P/CAF in the immunopellet 
by immunoblot. The results indicate that under 
our experimental conditions, P/CAF and HDAC3 
interacted in vivo (Figure 6B, lane 3). The same 
results were obtained using P/CAF-FL (data not 
shown). 
 
Apoptosis induces P/CAF cytoplasmic 
accumulation 
Although P/CAF is known to be a 
nuclear protein (there are, however, a few 
examples of P/CAF cytoplasmic localization) 
[see (17,38)], we investigated whether 
endogenous P/CAF would localize to the 
cytoplasm under different conditions. It has been 
proposed that P/CAF may have a role in 
apoptosis and DNA damage response due to its 
ability to acetylate p53, E2F1, and Ku70 
(9,13,24-27). Thus, we investigated whether 
P/CAF could localize in the cytoplasm during 
apoptosis. To do this, we UV irradiated 
CV1COS cells. We then determined endogenous 
P/CAF localization by immunostaining with an 
antibody that specifically recognizes P/CAF. 
Apoptosis induction was followed by staining 
with fluorescent annexin V. In apoptosis, 
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endogenous P/CAF partially accumulated in the 
cytoplasm (Figure 7A). Then, we analyzed  
P/CAF localization throughout the apoptotic 
progression. To do that endogenous P/CAF 
localization was analyzed at different times after 
UV irradiation. The results shown that 10 
minutes after UV irradiation P/CAF is clearly 
distributed between nucleus and cytoplasm. After 
30 min, P/CAF levels increase and it is still 
localized between nucleus and cytoplasm. 
Finally, after 1 h, P/CAF is distributed between 
nucleus and cytoplasm and in most condensed 
cells is completely cytoplasmic (Figure 7A and 
B, see arrowheads). Similar results were obtained 
when apoptosis was induced by treatment with 
dexamethasone (Figure 7C and D). These results 
suggest that apoptosis induces P/CAF 
cytoplasmic accumulation. 
 
DISCUSSION 
 
The results show that P/CAF 
intramolecular acetylation is required for P/CAF 
nuclear localization. Lysines are essential 
components of NLS (45), and are often 
acetylated. It has been proposed that lysine 
acetylation regulates the nuclear/cytoplasmic 
distribution of several proteins [see reviews by 
(46,47)]. This modification could regulate NLS 
function by affecting NLS interactions with 
nuclear import machinery. Alternatively, 
acetylation within the NLS could induce 
conformational changes that affect NLS or 
nuclear export signal (NES) functions and alter 
protein subcellular distribution, as has been 
described for several proteins (48-54). Our 
results indicate that P/CAF NLS acetylation does 
not increase P/CAF’s ability to recognize 
importin machinery. In addition, blocking 
nuclear export did not affect either P/CAF(352-
832) (nuclear) or P/CAF(352-832)ΔHAT  
(cytoplasmic) localization. This suggests that 
some additional mechanisms (probably related to 
protein degradation) are responsible for the 
observed P/CAF intracellular distribution. 
Although P/CAF is a histone 
acetyltransferase, like CBP and p300, it has also 
been recognized as a critical regulator of 
nonhistone proteins involved in many cellular 
processes, such as differentiation and apoptosis 
(55). In yeast, loss of the P/CAF homologous 
Gcn5l2 leads to high levels of apoptosis (56). 
The apoptosis regulators p53, p73, and E2F1 
have been shown to be regulated by P/CAF 
acetylation (9,24-27,57) in response to DNA 
damage. In addition, P/CAF associates with 
Ku70 in vivo, acetylates its C-terminal linker, 
and blocks the ability of Ku70 to suppress Bax-
mediated apoptosis, indicating that acetylation 
negatively regulates the antiapoptotic function of 
Ku70 (13). Interestingly, the Ku70 pool 
responsible for Bax sequestration is cytoplasmic 
(58), suggesting that P/CAF acetylation takes 
place in the cytoplasm. Relocalization of P/CAF 
from the nucleus to the cytosol following cellular 
damage might be a key regulatory step in Bax-
mediated apoptosis. Our results provide evidence 
for a molecular mechanism that regulates P/CAF 
subcellular redistribution by autoacetylation 
following DNA damage. Additional experiments 
will be needed to determine what signals regulate 
P/CAF autoacetylation under proapoptotic 
conditions. It is possible that P/CAF interacts 
with the apoptotic regulator PKCd, which has 
been shown to inhibit the HAT activity of p300 
(59). It should also be noted that cytoplasmic 
relocalization of HDAC3 is important for 
apoptosis progression (35).  
In addition to a possible P/CAF 
cytoplasmic function, the ability of cytoplasmic 
P/CAF to interact with the transcriptional 
machinery in the nucleus is reduced. It would be 
interesting to address whether the cytoplasmic 
localization of nonautoacetylated P/CAF has a 
function, such as repressing transcription by 
potentially sequestering positive transcriptional 
components. Alternatively, it may be part of a 
mechanism that prevents P/CAF outside of the 
nucleus from taking part in any further action, 
such as global histone H3 
acetylation/deacetylation, after apoptosis is 
induced (34,35). 
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FIGURE LEGENDS 
 
Figure 1. P/CAF lacking HAT activity localizes in the cytoplasm 
(A–C) Schematic representation of P/CAF proteins (A), showing the NLS and acetylated lysines. 
Relative HAT activity (B) and P/CAF autoacetylation (C) of GST (control), GST-P/CAF(352-832), 
GST-P/CAF(352-832)∆HAT, and GST-P/CAF(352-832)L606A. Acetylated proteins were visualized 
by fluorography. Ac-P/CAF, acetylated P/CAF. 
(D) Localization in transfected CV1COS cells of P/CAF(352-832), that we named as P/CAF, 
P/CAF(352-832)∆HAT, that we named as P/CAF∆HAT, or P/CAF(352-832)L606A, that we named as 
P/CAF-L606A.  
(E) Localization in transfected CV1COS cells of P/CAF-FL and P/CAF∆HAT-FL. 
 For (D) and (E), the bar graphs show the percentage of cells with predominantly nuclear (N) or 
cytoplasmic (C) localization or both (N+C) for over 200 cells from four independent experiments. 
Anti-P/CAF antibody, red; DAPI to reveal DNA, blue. 
 
Figure 2. P/CAF nuclear localization correlates with autoacetylation 
(A) Immunoprecipitation of P/CAF, P/CAF∆HAT, P/CAF-L606A, or vector alone from transfected 
CV1COS cells. P/CAF proteins were immunoprecipitated using an anti-P/CAF antibody, and 
immunocomplexes were tested for P/CAF acetylation status by immunoblot using antibodies that 
recognize acetylated lysines (Anti-AcLys, top blot) and P/CAF (Anti-P/CAF, bottom blot).  
(B) CV1COS cells were transfected as in (A) and treated with 0, 100, or 150 nM TSA for 18 h. 
Twenty-four hours after transfection, the localization of the expressed proteins was visualized by 
immunofluorescence staining using anti-P/CAF antibody (red). Cells were costained with DAPI to 
reveal DNA (blue). The results shown are representative of at least three independent experiments. 
 
Figure 3. P/CAF nuclear import is not regulated by autoacetylation 
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(A) In vitro pull-down assay of GST, GST-P/CAF(352-832) (P/CAF), and in vitro autoacetylated 
GST-P/CAF(352-832) (Ac-P/CAF) fusion proteins bound to in vitro–translated and radiolabelled 
importin α1. Input represents 50% of total importin α1 input. The diagrams show the percentage of 
importin α1 bound to P/CAF. 
(B) In vitro pull-down assay of GST and GST-importin β fusion proteins bound to in vitro–translated 
and radiolabelled P/CAF and Ac-P/CAF . The input represents 5% of the total P/CAF input.  
(C) Pull-down assay with whole-cell extracts of CV1COS cells transfected with P/CAF or 
P/CAF∆HAT and loaded on the following columns: GST (lane 2), GST-importin α1 (lane 4), and 
GST-importin β (lane 3). The bar graphs show the percentage of importin α1 or β bound to transfected 
P/CAF and P/CAF∆HAT.  
 
Figure 4. Proteasome inhibition partially reverses P/CAF cytoplasmic accumulation  
(A) Localization of P/CAF, P/CAF∆HAT, and GFP-Sirt2 (control) in transfected CV1COS cells 
treated with 0 or 20 nM LMB. Localization of the expressed proteins was analyzed by 
immunofluorescence staining using anti-P/CAF antibody (red). Cells were costained with DAPI to 
reveal DNA (blue).  
(B) Localization of P/CAF and P/CAF∆HAT in transfected CV1COS cells treated with 0 or 10 uM 
MG132. Localization of the expressed proteins was analyzed by immunofluorescence staining using 
anti P/CAF antibody (red). Cells were costained with DAPI to reveal DNA (blue). The bar graphs 
show the percentage of cells with predominantly nuclear (N) or cytoplasmic (C) localization or both 
(N+C) for over 200 cells from three independent experiments.  
 
Figure 5. P/CAF deacetylation by HDAC3 promotes P/CAF cytoplasmic accumulation 
(A) CV1COS cells were transfected with P/CAF and one of the following: Flag-HDAC1, HDAC2, 
Flag-HDAC3, HDAC4, or SIRT1. Localization of the expressed proteins was visualized by 
immunofluorescence staining using anti-P/CAF antibody (red). The bar graphs show the percentage of 
cells with predominantly nuclear (N) or cytoplasmic (C) localization or both (N+C) for over 300 cells 
from four independent experiments. The expression levels of Flag-HDAC1, HDAC2, Flag-HDAC3, 
HDAC4, and SIRT1 were similar (data not shown).  
(B) CV1COS cells were transfected with P/CAF, Flag-HDAC3, shRNAHDAC3 or shRNA Control. 
Localization of the expressed P/CAF and Flag-HDA3 proteins was visualized by immunofluorescence 
staining using anti-P/CAF antibody and anti-Flag antibodies respectively. Cells were costained with 
DAPI to reveal DNA (blue). 
(C) CV1COS cells were transfected with P/CAF (lane 1), P/CAF and Flag-HDAC3 (lane 2), or Flag-
HDAC3 alone (lane 3). P/CAF was immunoprecipitated using an anti P/CAF antibody. The 
immunocomplexes were tested for P/CAF acetylation status by immunoblot using antibodies that 
recognize acetylated lysines (anti-AcLys, top blot) and P/CAF (anti-P/CAF, bottom blot).  
(D) CV1COS cells were transfected as in (B) and treated with 0 or 150 nM TSA. P/CAF localization 
was visualized by immunofluorescence staining using anti-P/CAF antibody (red). TSA activity was 
followed by immunofluorescence staining using anti-Ac-H3 antibody (green) (increased Ac-H3 levels 
are indicated by white arrowheads). Cells were costained with DAPI to reveal DNA (blue). P/CAF 
proteins were immunoprecipitated using an anti P/CAF antibody. The immunocomplexes of P/CAF 
were tested for P/CAF acetylation status by immunoblot, using antibodies that recognize acetylated 
lysines (anti-Ac-Lys, top blot) and P/CAF (anti-P/CAF, bottom blot). The results shown are 
representative of at least three independent experiments. 
(E) CV1COS cells were transfected with P/CAF and/or Flag-HDAC3. P/CAF proteins were 
immunoprecipitated using an anti-P/CAF antibody in RIPA buffer. The immunocomplexes were tested 
for P/CAF HAT activity in an in vitro HAT assay and for the presence of P/CAF protein by 
immunoblot analysis.  
(F) CV1COS cells were transfected with P/CAF-FL and Flag-HDAC3 in the presence or absence of 
150 nM TSA for 12 h . Localization of the expressed P/CAF and Flag-HDA3 proteins was visualized 
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by immunofluorescence staining using anti-P/CAF and anti-Flag antibodies respectively. Cells were 
costained with DAPI to reveal DNA (blue). 
 
Figure 6. P/CAF binds HDAC3 to promotes P/CAF deacetylation 
(A) CV1COS cells were transfected with P/CAF and/or Flag-HDAC3 and the localization of the 
expressed proteins was analyzed by immunofluorescence staining using anti-P/CAF (red) and anti-
Flag (green) antibodies. Cells were costained with DAPI to visualize DNA (blue). 
(B) CV1COS cells were transfected as in (A). P/CAF was immunoprecipitated using an anti-P/CAF 
antibody. The immunocomplexes were tested for the presence of Flag-HDAC3 protein by immunoblot 
using antibodies against P/CAF (top blot) and the Flag epitope (bottom blot). 
 
Figure 7. Apoptosis induces P/CAF cytoplasmic accumulation 
(A) CV1COS cells were irradiated with 200 J/m2 UV for 0 or 60 min. Localization of endogenous 
P/CAF was analyzed by immunofluorescence staining using anti-P/CAF antibody (red). Cells were 
costained with DAPI to visualize DNA (blue) and with fluorescent annexin V to follow apoptotic 
cells.  
(B) Cells were treated as in  (A) and P/CAF localization was analyzed at different times. 
(C) CV1COS cells were treated with 2 muM dexamethasone for 0 or 60 min. Localization of 
endogenous P/CAF was analyzed by immunofluorescence staining using anti-P/CAF antibody (red). 
Cells were costained with DAPI to visualize DNA (blue) and with fluorescent annexin V to follow 
apoptotic cells.  
(D) Cells were treated as in  (C) and P/CAF localization was analyzed at different times. 
The results shown are representative of at least three independent experiments. Arrowheads mark cells 
with  complete P/CAF cytoplasmic localization.  
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